Can-Fite BioPharma Files Two New Patent Applications Relating To Very Important Therapeutic Indications

PETACH TIKVA, Israel--(BUSINESS WIRE)--March 13, 2006--Can-Fite BioPharma (TASE:CFBI), a world leader in development of drugs that are agonists of the A3 adenosine receptor (A3AR agonists), announced today on the recent filing of two new patent one concerning the use of A3AR agonists for the treatment of osteoarthritis (OA) and the other for the treatment of dry eye syndrome. Both are very important therapeutic indications with very large commercial potential.